Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a report on Wednesday, February 26th.

Minerva Neurosciences Trading Up 0.8 %

Minerva Neurosciences stock opened at $1.87 on Wednesday. The firm has a market capitalization of $13.04 million, a price-to-earnings ratio of -4.24 and a beta of 0.10. The firm’s fifty day moving average price is $1.94 and its two-hundred day moving average price is $2.25. Minerva Neurosciences has a 1-year low of $1.42 and a 1-year high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.49. On average, research analysts forecast that Minerva Neurosciences will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC lifted its holdings in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,764 shares of the biopharmaceutical company’s stock after buying an additional 8,525 shares during the period. Citadel Advisors LLC owned approximately 0.37% of Minerva Neurosciences worth $57,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.